Zydus Lifesciences trades higher on getting post application action letter for cGMP, PAI at Ahmedabad facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 974.95, up by 12.90 points or 1.34% from its previous closing of Rs. 962.05 on the BSE.
The scrip opened at Rs. 962.00 and has touched a high and low of Rs. 982.10 and Rs. 958.55 respectively. So far 94414 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 964.50 on 06-Mar-2024 and a 52 week low of Rs. 461.50 on 13-Mar-2023.
Last one week high and low of the scrip stood at Rs. 982.10 and Rs. 920.50 respectively. The current market cap of the company is Rs. 98689.90 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.03% and 6.99% respectively.
Zydus Lifesciences has received Post Application Action Letter from the USFDA for the inspection conducted at the Ahmedabad API facility of the company, confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API.
This facility underwent for-cause cGMP surveillance and Pre-Approval Inspection for manufacturing of drug substances Enzalutamide from December 14 to 22, 2023.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
